Mobile

A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes melli...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001765-28

A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to determine the efficacy of taspoglutide based on glycemic control (as assessed by HbA1c) compared with placebo in drug-naïve patients with type 2 diabetes after 24 weeks of treatment

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens